Showing results (141-150 of 169) with videos related to
Sort By:
Pageof 17
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerStephen Chan, Max E Scheulen, Stephen Johnston, et al.Epilepsia|June 30, 2012
Design and phenomenology of the FEBSTAT studyDale C Hesdorffer, Shlomo Shinnar, Darrell V Lewis, et al.The Oncologist|July 16, 2013
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive markerCristina Saura, Ling-Ming Tseng, Stephen Chan, et al.Epilepsia|June 7, 2016
Risk factors for subsequent febrile seizures in the FEBSTAT studyDale C Hesdorffer, Shlomo Shinnar, Daniel N Lax, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerXavier Pivot, Alexey Manikhas, Bogdan Żurawski, et al.Liver Cancer|April 18, 2018
Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular CarcinomaTom Tan-To Cheung, Philip Chong-Hei Kwok, Stephen Chan, et al.Journal of the American College of Radiology : JACR|March 11, 2026
Saving Academic Radiology: Summary of the 2025 ACR Intersociety MeetingJay R Parikh, Erin S Schwartz, Laeton J Pang, et al.Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.Pageof 17